跳至主要内容
临床试验/JPRN-UMIN000011137
JPRN-UMIN000011137已完成未知

The effect of beraprost sodium on the surrogate markers of atherosclerosis in type 2 diabetes mellitus - The effect of beraprost sodium on the surrogate markers of atherosclerosis in type 2 diabetes mellitus

Department of Metabolic Medicine Osaka University Graduate School of Medicine0 个研究点目标入组 25 人开始时间: 2013年7月6日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patient whom beraprost sodium is contraindicated for Patient who takes vasodilator (nitrates) Patinet who has been started anitiplatelet drugs and/or drugs for dyslipidemia within 3 months before starting beraprost sodium Patinet who have been changed drugs for diabetes mellitus within 3 months before starting beraprost sodium Patient whose ABI is less than 0.9 Patinet who take glucocorticoids and NSAID (except aspirin) Patient who has the impairment of renal function (Cr more than 2 mg/dl) Patient who is unsuitable for this study (judged by a doctor)

研究者

发起方
Department of Metabolic Medicine Osaka University Graduate School of Medicine

相似试验